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Poster Session I S211Infusions were well tolerated, and both WBC . 1000 and ANC .
500 were reached on day 110.5 (7-11). CryoStor CS10 has demon-
strated benefits in comparison to the previous standard CFM in
terms of cell recovery post-thaw, particularly providing improved
stability after 20 to 60min storage at room temperature (RT) in these
validation experiments, as well as demonstrating clinical tolerance in
initial patient applications. Further data will be collected to validate
the outcome of hematopoietic regeneration after reinfusion.156
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Background: Perinatal hypoxia/ischemia (H/I) is a brain distur-
bance due to the absence or decrease in oxygen supplementation in
newborns, and represents a leading cause of neurologic injury. Neu-
rological sequelae include cerebral palsy (CP), epilepsy, and cogni-
tive deficit. The reparative, regenerative, and replicative properties
of hematopoietic cells have shown that they could be a potential
treatment of several neurological conditions, including chronic brain
damage. It has been found that hematopoietic cells may be trans-
ported through the cerebrospinal fluid and be delivered more effi-
ciently to the injured area after their introduction in the
subarachnoid space of the spinal cord when compared with the intra-
venous route. The objective of this study is to report the safety and
efficacy of the intrathecal autologous total nucleated cell injection
in the treatment of children with H/I brain injury.
Methods: We included patients with H/I brain injury between 1
month and 8 years old. Patients were evaluated clinically with the
Battelle Developmental Inventory (BDI) and with magnetic reso-
nance images (MRI) before mobilization. Subcutaneous growth-col-
ony stimulation factor was used for 4 days prior to the bone marrow
(BM) harvest. The buffy coat was obtained through centrifugation of
the BM. Total nucleated cells (TNC) were infused through lumbar
puncture, and the red cell concentrate with a residual amount of
TNC was administered intravenously.
Results:Eighteen patients were included, 13 male and 5 female with
a median age of 3 (0 - 8) years and a mean weight of 12.6 (SD 6.7) kg.
A median of 13.3 (1 - 39)  106 CD341 cells in a volume of 7.5 (4 –
10.5) mL were infused intrathecally, and 5.45 (0.5 - 60)  106
CD341 cells in 49.5 (6 – 181) mL were applied intravenously.
Mild anesthetic complications were presented in 2 patients, while
4 had other minor side effects. Twelve patients have reached the
30-day follow-up, showing an increase in BDI equivalent age (11
[1 – 62] vs 11.5 [3 – 74] months, P5 .004).Seven patients have com-
pleted the 6-month follow-up, increasing BDI equivalent age from
14 (1 - 62) to 17 (5 - 73) months (P 5 .016). There have been no
changes yet in any of the MRI comparisons.
Conclusions: This procedure proved to be safe, with minimal side
effects, and may result beneficial in patients’ development. However,
it will be necessary a phase II clinical trial to consider this approach as
a therapeutic option.Table 1. Comparison of the BDI results between days 0 and +30.
Area
Personal/
Social Adaptative Motor skills Com
Day 0 64.5 (3 - 154) 26.5 (4 - 97) 12.5 (3 - 157) 17.5
Day +30 67 (10 - 168) 28.5 (12 - 113) 19 (8 - 155) 19
P value* .013 .054 .005
*Wilcoxon test157
DELICATE BALANCE BETWEEN REGULATION AND STIMULATION AT THE
ANTIGEN PRESENTING CELL SITE DETERMINES THE LIKELIHOOD OF
SUCCESSFUL IN-VITRO PRIMING AND ENRICHMENT OF LEUKEMIA-RE-
ACTIVE T CELLS FROM THE NA€IVE DONOR REPERTOIRE
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Falkenburg, J.H.F. Leiden University Medical Center, Leiden, Nether-
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Although the in-vitro induction of leukemia-reactive T cells from
the na€ıve donor repertoire has been shown to be feasible, the robust-
ness of the procedure is limited. In this study, we investigated the role
of the frequencies of antigen-specific precursor T cells (Tprec) and
regulatory T cells (Treg), the number of antigen presenting cells
(APC), and the number of targeted antigens (Ag) on the ability to
prime, enrich and expand Ag-specific T cells from primary immune
responses in-vitro. Therefore, we developed an in-vitro model sys-
tem allowing quantitative and functional monitoring of Ag-specific
activation and proliferation of individual donor T cells in the first
14 days of the immune response. In this model, we exposed na€ıve
PKH-labeled Tprec to allogeneic APC in different responder/stim-
ulator (R/S) ratios in the presence of different numbers of innocent
bystander cells. Optimal T cell activation was seen at specific
Tprec/S ratios between 1/1 and 1/5, irrespective of the number of in-
nocent bystander cells. Lowering the number of stimulator cells per
Tprec resulted in incomplete activation and proliferation, but more
importantly, exposure to an excess of stimulator cells resulted in in-
duction of activation-induced cell death (AICD) of the Ag-specific
Tprec. Interestingly, when cells with an inferior APC phenotype
(e.g. primary leukemic cells) were used as stimulator cells, activation
curves were of similar shape but shifted towards higher APC
amounts, resulting in optimal stimulation at 1/100 Tprec/S ratios.
Treg were like Tprec attracted to the site of the APC and their acti-
vation further increased their inhibitory potential. Especially when
they were at a numeric advantage, Treg were capable of impairing
Ag-specific Tprec priming. Increasing the number of Ag-specific
Tprec by simultaneous targeting of multiple antigens in combina-
tion with Treg depletion strongly increased the reproducibility of
in-vitro priming and expansion of Ag-specific T cells. In conclusion,
the in-vitro generation of Ag-specific primary immune responses can
only be successfully and reproducibly performed by creating an op-
timal balance at the priming site of the immune response (e.g. the
APC) between the numbers of negative regulators (Treg) and re-
sponding cells (Tprec). Using these insights we developed a standard
operating procedure for the reproducible in-vitro induction and
selection of leukemia-reactive T cells for adoptive transfer using leu-
kemic APC as stimulator cells.158
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Introduction: Adoptive immunotherapy using donor-derived cellu-
lar effectors can restore anti-viral immunity after allogeneic stem cell
transplantation. We have developed a method for the production of
a T cell product specific for multiple viruses that does not rely on
EBV transformed cells for stimulation.unication Cognitive Global BDI equivalent age
(5 - 115) 13 (1 - 93) 148 (28 - 576) 11 (1 - 62)
(6 - 115) 14.5 (2 - 104) 156 (60 - 640) 11.5 (3 - 74)
.005 .007 .004 .004
